SLAMF9

Across TCGA pan-cancer cohorts, SLAMF9 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLAMF9 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SLAMF9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLAMF9 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

HNSC, BLCA, and SKCM are the cancer types where SLAMF9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.156	0.751	<.001	48	view →
BLCA	OS	Median	All	0.233	0.610	.017	12	view →
SKCM	DFS	Median	III,IV	0.872	0.464	.028	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SLAMF9–HNSC (OS)

Open the HNSC breakdown →